Survodutid

A peptide that acts on both GLP-1 and glucagon receptors simultaneously, currently in advanced clinical trials related to metabolic regulation.

Survodutide is a dual agonist at GLP-1 and glucagon receptors, developed by Boehringer Ingelheim in collaboration with Zealand Pharma. It is being studied in phase 3 trials for weight regulation in obesity as well as in metabolic dysfunction-associated steatohepatitis (MASH), and is not approved as a medication in any country to date.

Facts

• CAS number: 2805997-46-8
• Molecular weight: 4232 g/mol

Evidence

• In a randomized phase 3 trial with 725 adults with obesity without diabetes, survodutide led to a mean body weight loss of 12 to 13 percent after 76 weeks, compared with 5 percent under placebo. Le Roux CW et al. 2026, New England Journal of Medicine, DOI 10.1056/NEJMoa2600751
• In a randomized phase 2 trial with 386 adults with obesity, survodutide led to a body weight loss of up to 14.9 percent in the highest-amount group after 46 weeks, compared with 2.8 percent under placebo. le Roux CW et al. 2024, The Lancet Diabetes & Endocrinology 12:162-173, PMID 38330987
• In a phase 2 trial with 293 people with MASH and liver fibrosis, up to 62 percent of participants on survodutide showed histologic improvement of MASH with no worsening of fibrosis after 48 weeks, compared with 14 percent under placebo. Sanyal AJ et al. 2024, New England Journal of Medicine, PMID 38847460

Frequently asked questions

Is survodutide already available as a medication?
No. Survodutide is currently in phase 3 trials, with FDA approval expected at the earliest in 2027 according to the manufacturer. It is currently not an approved medication.

What sets survodutide apart from semaglutide?
Semaglutide acts only on the GLP-1 receptor, while survodutide additionally acts on the glucagon receptor. Clinical trials showed this dual action also reduces liver fat content alongside the effect on body weight.

Where does survodutide come from?
Survodutide was developed by the pharmaceutical company Boehringer Ingelheim and is being studied in several phase 3 trials under the SYNCHRONIZE program name, partly in collaboration with Zealand Pharma.

Documented prices

List prices excluding shipping and discounts. Currency and product variants must be compared separately. Availability and delivered batch have not been verified.

No comparable documented prices are available.